Skip to main content

Mark Roskey, PhD, chief scientific officer at Quanterix, provided clinical insight on the function of the company’s Simoa technology and the incorporation of various biomarkers to aid in the diagnosis of Alzheimer disease.:

Source: Neurology Read More